Prednisone
- Generic Name
- Prednisone
- Brand Names
- Deltasone, Rayos, Winpred
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O5
- CAS Number
- 53-03-2
- Unique Ingredient Identifier
- VB0R961HZT
- Background
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
Prednisone was granted FDA approval on 21 February 1955.
- Indication
Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.
- Associated Conditions
- Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- Palliative Treatment
Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone
Phase 2
Not yet recruiting
- Conditions
- Interventions
- Drug: Abiraterone acetateDrug: PrednisoneDrug: Hyperpolarized [1-13C] pyruvate (HP 13C)Procedure: Magnetic Resonance Imaging (MRI)Procedure: Non-investigational radical prostatectomy (RP)Procedure: Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) PET/Computerized tomography (CT)
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Ivan de Kouchkovsky, MD
- Target Recruit Count
- 32
- Registration Number
- NCT06384222
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial
Phase 2
Recruiting
- Conditions
- Interventions
- Drug: AbirateroneDrug: ApalutamideProcedure: Biospecimen CollectionProcedure: Bone ScanProcedure: Computed TomographyDrug: DarolutamideDrug: DegarelixDrug: EnzalutamideDrug: GoserelinDrug: HistrelinDrug: LeuprolideProcedure: Magnetic Resonance ImagingOther: Patient ObservationProcedure: Positron Emission TomographyDrug: PrednisoneOther: Questionnaire AdministrationDrug: RelugolixRadiation: Stereotactic Body Radiation TherapyDrug: Triptorelin
- First Posted Date
- 2024-04-23
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 120
- Registration Number
- NCT06378866
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD
Phase 4
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 118
- Registration Number
- NCT06364319
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 850
- Registration Number
- NCT06356129
- Locations
- 🇺🇸
Cancer Care Specialists, Reno, Nevada, United States
🇺🇸Local Institution - 0498, East Brunswick, New Jersey, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 220
- Registration Number
- NCT06353386
- Locations
- 🇨🇦
Centre Hospitalier de l'Université de Montréal ( Site 0200), Montréal, Quebec, Canada
🇵🇱Uniwersyteckie Centrum Kliniczne ( Site 1405), Gdansk, Pomorskie, Poland
🇬🇧Addenbrooke's Hospital ( Site 1902), Cambridge, Cambridgeshire, United Kingdom
177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Rohan Garje
- Target Recruit Count
- 30
- Registration Number
- NCT06329830
- Locations
- 🇺🇸
Miami Cancer Institute, Miami, Florida, United States
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Phase 2
Not yet recruiting
- Conditions
- Interventions
- Procedure: Biospecimen CollectionDrug: Asparaginase Erwinia chrysanthemiProcedure: Bone Marrow AspirationProcedure: Computed TomographyBiological: BlinatumomabDrug: Calaspargase PegolDrug: CyclophosphamideDrug: CytarabineDrug: DaunorubicinDrug: PrednisoloneDrug: DexamethasoneDrug: PrednisoneDrug: DoxorubicinProcedure: EchocardiographyProcedure: FDG-Positron Emission TomographyDrug: LeucovorinProcedure: Lumbar PunctureProcedure: Magnetic Resonance ImagingDrug: MercaptopurineDrug: MethotrexateProcedure: Multigated Acquisition ScanDrug: PegaspargaseDrug: Therapeutic HydrocortisoneDrug: ThioguanineDrug: VenetoclaxDrug: Vincristine
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 171
- Registration Number
- NCT06317662
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-03-15
- Target Recruit Count
- 300
- Registration Number
- NCT06313996
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 790
- Registration Number
- NCT06284122
- Locations
- 🇫🇷
HOPITAL HENRI MONDOR - Unité Hémopathies Lymphoïdes, Créteil, France
🇫🇷GUSTAVE ROUSSY CANCER CAMPUS GRAND PARIS - Département Médecine Oncologique, Villejuif, France
🇫🇷CH ANNECY GENEVOIS - SITE D'ANNECY - Service Hématologie, Pringy, France
Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-02-09
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
- Target Recruit Count
- 112
- Registration Number
- NCT06251180
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath